Skip to Main Content

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. Our agenda is exceedingly modest. We have absolutely nothing planned, which means, hopefully, catching up on napping and reading. But what about you? Summer is now officially here, and so this might be a good time to plan a getaway or enjoy the great outdoors now, while you have the chance. You could also make time for someone special or simply try something entirely different. Well, whatever you do, have a grand time. But, be safe. Enjoy and see you soon …

A Pfizer biosimilar version of Epogen, an anemia drug, was rejected for the second time by the Food and Drug Administration. The drug maker pointed to an agency warning letter issued in February over problems with a plant in McPherson, Kan., which Pfizer inherited as part of its Hospira acquisition. The same plant is contracted to make a version of Teva Pharmaceuticals’s Copaxone for Momenta Pharmaceuticals, which has also run into delays.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.